RPG Life Sciences completes API business transfer to subsidiary
RPG Life Sciences Limited finalized the slump sale of its API business to subsidiary RPG Active Pharma Limited on August 15, 2026. The company notified stock exchanges via a SEBI Regulation 30 filing, following the execution of the Business Transfer Agreement in July 2026.

*this image is generated using AI for illustrative purposes only.
RPG Life Sciences Limited has completed the transfer of its Active Pharmaceutical Ingredients (API) business to RPG Active Pharma Limited, a wholly owned subsidiary. The transaction was executed on a slump sale basis and became effective on August 15, 2026.
The company disclosed the completion in a letter dated August 15, 2026, addressed to the National Stock Exchange of India Limited and BSE Limited. This follows a previous intimation issued on July 29, 2026, regarding the execution of the Business Transfer Agreement.
Regulatory Disclosure
The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The move consolidates the API operations within the subsidiary structure, as confirmed by Rajesh Shirambekar, Head – Legal & Company Secretary.
Historical Stock Returns for RPG Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.70% | +3.47% | -1.44% | +40.90% | +21.95% | +417.20% |
How will the separation of API operations into RPG Active Pharma Limited impact RPG Life Sciences' consolidated revenue and profit margins in upcoming fiscal quarters?
What are the strategic reasons for consolidating API operations under a wholly owned subsidiary, and does this signal a potential future IPO or spin-off for RPG Active Pharma?
Will this structural change affect existing supply chain agreements or customer contracts held by the parent company, and if so, how will transition risks be mitigated?


































